INCR Intercure Ltd

InterCure Ltd. (TSX: INCR.U, TASE: INCR)(dba Canndoc)(the “Company”) is pleased to announce that further to its confidential filing with the U.S. Securities and Exchange Commission (the "SEC") of its 20F registration statement on April 20, 2021, it has filed its 20F registration statement pursuant to Securities Exchange Act of 1933 and F-1 registration statement under the Securities Act of 1933. The full statements are available on the Company’s SEDAR profile as well as on EDGAR:

20-F: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016836/form20fr12b.htm

F-1: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016926/formdrsf-1.htm

Listing on the NASDAQ is subject to satisfaction of all applicable listing and regulatory requirements, including registration of the Common Shares with the SEC, NASDAQ requirements and approvals. Following receipt of all required approvals, the Company will issue a press release announcing its first trading day on the NASDAQ.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (TSX:INCR.U, TASE:INCR) is the leading, fastest growing and the most profitable Israeli cannabis company. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to be the most profitable cannabis company globally outside of North America.

InterCure is listed on the Toronto Stock Exchange under the symbol INCR.U and trades on the Tel Aviv Stock Exchange under the symbol INCR.TA. Subject to the satisfaction of the listing conditions of the NASDAQ, InterCure’s common shares are expected to commence trading on the NASDAQ during the last week of July 2021 and will trade under the symbol “INCR”.

For more information, visit: http://www.intercure.co

Forward-Looking Statements

This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects InterCure’s current expectations regarding future events. The words “will”, “expects”, “intends”, "plans" and similar expressions are often intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Specific forward-looking information contained in this press release includes, but is not limited to: the listing of the Common Shares on NASDAQ. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions. InterCure undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Contact:

InterCure Ltd.Amos Cohen, Chief Financial Officeramos@canndoc-pharma.com (972)77-460-5012